We also showed, for the first time, that by knocking out the MLH1 gene and inducing MMR deficiency in neuroblastoma tumors they became more immunogenic and highly infiltrated by effector cytotoxic CD8+ and CD4+ T cells, along with an increase in CD39+CD8+ tumor-specific T cells. The gene discussed is MLH1; the disease is mismatch repair cancer syndrome 1.